(Q38851096)

7 September 2017

1 reference

title

Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care (English)

1 reference

7 September 2017

5

M J Fritzler

1 reference

7 September 2017

M Y Choi

1

1 reference

7 September 2017

M R W Barber

series ordinal

2

1 reference

7 September 2017

C E H Barber

series ordinal

3

1 reference

7 September 2017

A E Clarke

series ordinal

4

1 reference

7 September 2017

publication date

1 July 2016

1 reference

7 September 2017

1 reference

7 September 2017

volume

25

1 reference

7 September 2017

issue

8

1 reference

7 September 2017

page(s)

838-849

1 reference

Systemic lupus erythematosus.

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Understanding the epidemiology and progression of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Epidemiology and survival of systemic lupus erythematosus in Hong Kong Chinese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

SLE patients with renal damage incur higher health care costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Prediction and prevention of autoimmune disease: a personal perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Are we at a stage to predict autoimmune rheumatic diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

SLE diagnosis and treatment: when early is early

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Preclinical systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Organ damage in patients with incomplete lupus syndromes: from a Chinese academic center

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Outcome of incomplete systemic lupus erythematosus after 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Development of SLE among "potential SLE" patients seen in consultation: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

The United States to Africa lupus prevalence gradient revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Prevalence of systemic lupus erythematosus and systemic sclerosis in the First Nations population of Alberta, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Microarray profiling of antiviral antibodies for the development of diagnostics, vaccines, and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Choosing wisely: Review and commentary on anti-nuclear antibody (ANA) testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Predicting and preventing autoimmunity, myth or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Prophylaxis of the antiphospholipid syndrome: a consensus report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Antinucleosome antibodies may help predict development of systemic lupus erythematosus in patients with primary antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Undifferentiated CTD: a wide spectrum of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Altered Th17 cells and Th17/regulatory T-cell ratios indicate the subsequent conversion from undifferentiated connective tissue disease to definitive systemic autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Systemic Lupus Erythematosus--A Disease with A Dysregulated Type I Interferon System.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Clinical Application of Plant Sterol and Stanol Products

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Pathology of systemic lupus erythematosus: the challenges ahead.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Can we personalize treatment for kidney diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

The kidney biopsy in lupus nephritis: is it still relevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Genetics of systemic lupus erythematosus. Clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Using genetics to deliver personalized SLE therapy-a realistic prospect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Occupational exposures and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Recent advances and opportunities in research on lupus: environmental influences and mechanisms of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Geoepidemiology of autoimmune rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Epigenetics and the microbiome: developing areas in the understanding of the aetiology of lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Prevention of autoimmune rheumatic disease: state of the art and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Cigarette smoking and radiographic progression in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Smoking and the risk of systemic lupus erythematosus: an updated systematic review and cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry VI: Effect of Cigarette Smoking on the Clinical Phenotype of Chinese Patients with Systemic Lupus Erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Prevention and management of co-morbidities in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Respiratory and immunologic consequences of marijuana smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

A global toxicogenomic analysis investigating the mechanistic differences between tobacco and marijuana smoke condensates in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Marijuana smoke condensate induces p53-mediated apoptosis in human lung epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Silica exposure and altered regulation of autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Silica-associated systemic erythematosus lupus or mineral dust lupus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Occupational exposures and risk of systemic lupus erythematosus: a review of the evidence and exposure assessment methods in population- and clinic-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Cigarette smoking, alcohol consumption and risk of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Moderate alcohol drinking might be protective for systemic lupus erythematosus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Alcohol consumption is not protective for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

The role of vitamin D supplementation in patients with rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Shining light on lupus and UV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Ultraviolet radiation and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Binding of antibodies to the extractable nuclear antigens SS-A/Ro and SS-B/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): implications for the pathogenesis of photosensitive cutaneous lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Ultraviolet light induces binding of antibodies to selected nuclear antigens on cultured human keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Antibodies to deoxyribonucleic acid irradiated with ultraviolet light: detection by precipitins and immunofluorescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Infectious antibodies in systemic lupus erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Viruses as potential pathogenic agents in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Immune Alterations in Patients with Anti-Interferon-γ Autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

21 January 2018

Lupus and Epstein-Barr

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

The Ro 60 kDa autoantigen comes into focus: interpreting epitope mapping experiments on the basis of structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Systemic Lupus Erythematosus: Molecular Mimicry between Anti-dsDNA CDR3 Idiotype, Microbial and Self Peptides-As Antigens for Th Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Aberrant Epstein-Barr viral infection in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Review article: BK virus in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

SLE: Another Autoimmune Disorder Influenced by Microbes and Diet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Toxoplasma gondii infection inhibits the development of lupus-like syndrome in autoimmune (New Zealand Black x New Zealand White) F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Changes in the cytokine profile of lupus-prone mice (NZB/NZW)F1 induced by Plasmodium chabaudi and their implications in the reversal of clinical symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

What is a clinical pathway? Development of a definition to inform the debate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Autoantibodies and SLE: the threshold for disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Choosing wisely: the Canadian Rheumatology Association's list of 5 items physicians and patients should question

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

The clinical utility of a positive antinuclear antibody test result

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Anti-brain antibodies are associated with more severe cognitive and behavioral profiles in Italian children with Autism Spectrum Disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Hydroxychloroquine: the cornerstone of lupus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Costs associated with severe and nonsevere systemic lupus erythematosus in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

The impact of flare on disease costs of patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Healthcare utilization and costs of systemic lupus erythematosus in Medicaid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Costs of illness and quality of life in patients with systemic lupus erythematosus in South Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Total cost and cost predictors in systemic lupus erythematosus - 8-years follow-up of a Swedish inception cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

A structured literature review of the direct costs of adult systemic lupus erythematosus in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

The frequency and outcome of lupus nephritis: results from an international inception cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

Impact of concurrent foot pain on health and functional status in people with knee osteoarthritis: data from the osteoarthritis initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203316640367

21 January 2018

Identifiers

DOI

10.1177/0961203316640367

1 reference

7 September 2017

1 reference